Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer

被引：0

作者：

Leyvraz, S. ^{[1
]}

Hong, D. S. ^{[2
]}

Shen, L. ^{[3
]}

van Tilburg, C. M. ^{[4
,5
]}

Tan, D. S. W. ^{[6
]}

Kummar, S. ^{[7
]}

Lin, J. J. ^{[8
,9
]}

Doz, F. ^{[10
,11
]}

McDermott, R. ^{[12
,13
]}

Albert, C. M. ^{[14
,15
]}

Berlin, J. ^{[16
]}

Bielack, S. ^{[17
]}

Lassen, U. N. ^{[18
]}

Tahara, M. ^{[19
]}

Norenberg, R. ^{[20
]}

Shurshalina, A. ^{[21
]}

Fellous, M. ^{[22
]}

Nogai, H. ^{[22
]}

Xu, R. ^{[23
]}

Laetsch, T. W. ^{[24
]}

Drilon, A. ^{[25
,26
]}

机构：

[1] Charite Comprehens Canc Ctr, Berlin, Germany

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[4] Heidelberg Univ Hosp, Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany

[5] German Canc Res Ctr, Heidelberg, Germany

[6] Natl Canc Ctr Singapore, Singapore, Singapore

[7] OHSU, Knight Canc Inst, Portland, OR USA

[8] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[9] Harvard Med Sch, Boston, MA 02115 USA

[10] Inst Curie, Paris, France

[11] Univ Paris, Paris, France

[12] St Vincents Univ Hosp, Dublin, Ireland

[13] Canc Trials Ireland, Dublin, Ireland

[14] Seattle Childrens Hosp, Seattle, WA USA

[15] Univ Washington, Sch Med, Seattle, WA USA

[16] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[17] Klinikum Stuttgart Olgahosp, Stuttgart, Germany

[18] Rigshosp, Dept Oncol, Copenhagen, Denmark

[19] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[20] Chrestos Concept GmbH & Co KG, Essen, Germany

[21] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[22] Bayer HealthCare Pharmaceut Inc, Basel, Switzerland

[23] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China

[24] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[25] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[26] Weill Cornell Med Coll, New York, NY USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V101

引用

页码：13 / 13

页数：1

共 50 条

[21] Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)
Cabanillas, Maria E.
Lin, Jessica Jiyeong
Brose, Marcia S.
McDermott, Raymond S.
Almubarak, Mohammed
Bauman, Jessica R.
Casanova, Michela
Kummar, Shivaani
Lee, Se-Hoon
Leyvraz, Serge
Oh, Do-Youn
Shen, Lin
Neu, Natascha
Bernard-Gauthier, Vadim
Mussi, Chiara E.
Hong, David S.
Drilon, Alexander E.
Waguespack, Steven G.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[22] Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib.
Drilon, Alexander
Kummar, Shivaani
Albert, Catherine M.
Nagasubramanian, Ramamoorthy
Hechtman, Jaclyn F.
Reeves, John A.
Beckmann, Georg
Rudolph, Marion
Wierzbinska, Justyna A.
Dima, Laura
Brega, Nicoletta
Laetsch, Theodore W.
Hong, David S.
CANCER RESEARCH, 2021, 81 (13)
[23] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
Andre, T.
Hong, D.
Deeken, J.
Italiano, A.
Liu, T.
Burcoveanu, D.
Norenberg, R.
Mussi, C.
Xu, R.
Drilon, A.
Shen, L.
ANNALS OF ONCOLOGY, 2023, 34 : S12 - S13
[24] LONG-TERM FOLLOW-UP OF THE EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER
Federman, Noah
Van Tilburg, Cornelis
Dierselhuis, Miranda
Albert, Catherine
Geoerger, Birgit
Dubois, Steven
Mascarenhas, Leo
Nagasubramanian, Ramamoorthy
Pappo, Alberto
Watt, Tanya
Bernard-Gauthier, Vadim
Norenberg, Ricarda
De la Cuesta, Esther
Doz, Francois
Zhang, Yizhuo
PEDIATRIC BLOOD & CANCER, 2023, 70
[25] Larotrectinib efficacy and safety in adult TRK fusion cancer patients.
Hong, David S.
Kummar, Shivaani
Farago, Anna F.
Lassen, Ulrik Niels
Berlin, Jordan
Schilder, Russell J.
McDermott, Raymond S.
Patel, Jyoti D.
Dowlati, Afshin
Doebele, Robert Charles
Tan, Daniel Shao-Weng
Lee, James J.
Nanda, Shivani
Childs, Barrett H.
Ku, Nora
Drilon, Alexander E.
Hyman, David Michael
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[26] Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
van Tilburg, Cornelis Martinus
DuBois, Steven G.
Albert, Catherine Michelle
Federman, Noah
Nagasubramanian, Ramamoorthy
Geoerger, Birgit
Orbach, Daniel
Bielack, Stefan S.
Shukla, Neerav Narendra
Turpin, Brian
Casanova, Michela
Spunt, Sheri L.
Qamoos, Hope
Nanda, Shivani
Childs, Barrett H.
Cox, Michael Craig
Pappo, Alberto S.
Laetsch, Theodore Willis
Mascarenhas, Leo
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Drilon, A. E.
Xu, R-H.
van Tilburg, C. M.
Doz, F.
Tan, D. S. W.
Lin, J. J.
Geoerger, B.
Zwaan, C. M.
Lassen, U. N.
Italiano, A.
Kummar, S.
McDermott, R. S.
Burcoveanu, D-I.
Neu, N.
Brega, N.
Laetsch, T.
Hong, D. S.
Shen, L.
ANNALS OF ONCOLOGY, 2024, 35 : S500 - S501
[28] Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC)
Cabanillas, Maria E.
Lin, Jessica Jiyeong
Brose, Marcia S.
McDermott, Raymond S.
Almubarak, Mohammed
Bauman, Jessica R.
Casanova, Michela
Kummar, Shivaani
Lee, Se-Hoon
Leyvraz, Serge
Oh, Do-Youn
Shen, Lin
Norenberg, Ricarda
Bernard-Gauthier, Vadim
Mussi, Chiara E.
Hong, David S.
Drilon, Alexander E.
Waguespack, Steven G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS
Perreault, Sebastien
Spano, Jean-Philippine
Nilsson, Anna
Deyell, Rebecca J.
Doz, Francois
Geoerger, Birgit
Gumus, Mahmut
Lassen, Ulrik N.
Nysom, Karsten
Valero-Arrese, Lorena
Idbaih, Ahmed
Bernard-Gauthier, Vadim
Neu, Natascha
Brega, Nicoletta
Drilon, Alexander
Laetsch, Theodore W.
van Tilburg, Cornelis M.
NEURO-ONCOLOGY, 2024, 26
[30] EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE CANCER: AN EXPANDED DATASET
Koga, Yuhki
PEDIATRIC BLOOD & CANCER, 2022, 69

← 1 2 3 4 5 →